BOLD - Audentes Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development106,66875,63948,66820,104
Selling General and Administrative30,00217,27511,2766,091
Non Recurring----
Total Operating Expenses136,67092,91459,94426,195
Operating Income or Loss-136,670-92,914-59,944-26,195
Income from Continuing Operations
Total Other Income/Expenses Net7,849430276-263
Earnings Before Interest and Taxes-136,670-92,914-59,944-26,195
Interest Expense----
Income Before Tax-128,821-92,484-59,668-26,458
Income Tax Expense--2,246--
Minority Interest----
Net Income From Continuing Ops-128,821-90,238-59,668-26,458
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-128,821-90,238-59,668-26,458
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-128,821-90,238-59,668-26,458